Rho: 'The hurdles are high when you have a drug that the world doesn’t need'

By Melissa Fassbender contact

- Last updated on GMT

Related tags: Rho, Quality by design, Regulations, Patient recruitment

Rho experts speak to the challenges facing drug development, meeting unmet needs, quality by design, and advances in technology, among other topics, during a sit-down at the CRO’s headquarters.

Today, it’s more difficult to develop a new medication that meets an unmet need, as products are more effective and safer than in the past, explained Jack Modell, MD, vice president and senior medical officer, Rho.

“It gets difficult with drug development because there are still a lot of unmet needs, a lot of opportunities, but they are harder to find, and the hurdles are higher because we’ve got better medications,”​ said Modell. “Therefore, the trials tend to be longer, larger, more expensive, and the regulatory hurdles even higher as well.”

The industry also struggles with clinical trial recruitment and ‘not getting the right patients,’ he said, noting the presence of ‘professional patients,’ among other challenges.

As one way to address this, Modell suggested the use of computerized assessments, such as interactive voice response. “For some things, computers are better than people,”​ he said during a discussion with Outsourcing-Pharma and colleague, Matt Healy, Rho vice president of clinical operations, at the company’s headquarters in Durham, NC.

“We’re at a point in time now where things are progressing faster than they ever have before,”​ said Healy, who cited the advent of technology and changes in guidances as key to this acceleration.

“The hurdles are high when you have a drug that the world doesn’t need,”​ added Modell. “But when you have a drug that the world needs and is waiting for … FDA and everybody else will do what they can to help get that drug approved.”

For the full conversation, watch the video above.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us

Products

View more

Webinars